Regeneron Pharmaceuticals, Inc. Financials

Market Capitalization $82.28 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	18.48
Forward PE	17.42
Price to Sales TTM	$5.74
Price to Book MRQ	$2.56
Enterprise to Revenue	5.16
Enterprise to EBITDA	16.89

Financial Reports as of Sep. 30, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-09-30
Profit Margin	32.13%
Operating Margin	29.56%
Return on Assets TTM	6.16%
Return on Equity TTM	15.19%

Income Statement

Revenue TTM	$14,247,799,808
Revenue per Share TTM	$134.76
Quarterly Revenue Growth	0.90%
Gross Profit TTM	$6,530,100,224
EBITDA	$5,041,800,000
Net Income to Common TTM	$4,577,999,872
Diluted EPS TTM	$41.76
Quarterly Earnings Growth YoY	8.90%

Balance Sheet

Total Cash MRQ	$8,443,599,872
Total Cash per Share MRQ	$82.30
Total Debt MRQ	$
Total Debt to Equity MRQ	8.74
Current Ratio MRQ	4.06
Book Value per Share MRQ	$301.15

Cash Flow

Operating Cash Flow TTM	$5,071,000,064
Levered Free Cash Flow TTM	$3,511,000,064

REGN Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	105,317,146
Float Shares	98,523,187
Avg 10 Volume	768,070
Avg 30 Volume	None
Shares Short	2,738,113
Short Ratio	2.42
Short % of Shares	2.75%
% Held by Insiders	2.02%
% Held by Institutions	90.19%

Stock Price Summary

Beta	0.37
Fifty Two Week Low	$476.49
Fifty Two Week High	$792.77
Fifty Two Week Change	7.74%
Day 50 MA	$707.31
Day 200 MA	$603.78

Dividends and Splits

Forward Annual Dividend Rate	$3.52
Forward Annual Dividend Yield	0.45%
Trailing Annual Dividend Rate	$3.52
Trailing Annual Dividend Yield	0.45%
Payout Ratio	6.33%
Dividend Date	2025-12-05
Ex Dividend Date	2025-11-20
Last Split Factor
Last Split Date